199 related articles for article (PubMed ID: 16638134)
1. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
Liu Y; Gao L; Gelman IH
BMC Cancer; 2006 Apr; 6():105. PubMed ID: 16638134
[TBL] [Abstract][Full Text] [Related]
2. SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways.
Gelman IH; Gao L
Mol Cancer Res; 2006 Mar; 4(3):151-8. PubMed ID: 16547152
[TBL] [Abstract][Full Text] [Related]
3. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis.
Lin X; Gelman IH
Cancer Res; 1997 Jun; 57(11):2304-12. PubMed ID: 9187136
[TBL] [Abstract][Full Text] [Related]
4. v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex.
Bu Y; Gelman IH
J Biol Chem; 2007 Sep; 282(37):26725-26739. PubMed ID: 17626016
[TBL] [Abstract][Full Text] [Related]
5. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
6. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.
Su B; Zheng Q; Vaughan MM; Bu Y; Gelman IH
Cancer Res; 2006 Jun; 66(11):5599-607. PubMed ID: 16740695
[TBL] [Abstract][Full Text] [Related]
7. SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway.
Su B; Bu Y; Engelberg D; Gelman IH
J Biol Chem; 2010 Feb; 285(7):4578-86. PubMed ID: 20018890
[TBL] [Abstract][Full Text] [Related]
8. Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src.
Bu Y; Gao L; Gelman IH
Int J Cancer; 2011 Apr; 128(8):1836-42. PubMed ID: 20568114
[TBL] [Abstract][Full Text] [Related]
9. A role for SSeCKS, a major protein kinase C substrate with tumour suppressor activity, in cytoskeletal architecture, formation of migratory processes, and cell migration during embryogenesis.
Gelman IH; Tombler E; Vargas J
Histochem J; 2000 Jan; 32(1):13-26. PubMed ID: 10805381
[TBL] [Abstract][Full Text] [Related]
10. Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12.
Su B; Gao L; Meng F; Guo LW; Rothschild J; Gelman IH
Oncogene; 2013 Apr; 32(16):2016-26. PubMed ID: 22710722
[TBL] [Abstract][Full Text] [Related]
11. Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia.
Akakura S; Huang C; Nelson PJ; Foster B; Gelman IH
Cancer Res; 2008 Jul; 68(13):5096-103. PubMed ID: 18593908
[TBL] [Abstract][Full Text] [Related]
12. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.
Lin X; Nelson P; Gelman IH
Mol Cell Biol; 2000 Oct; 20(19):7259-72. PubMed ID: 10982843
[TBL] [Abstract][Full Text] [Related]
13. Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12.
Guo LW; Gao L; Rothschild J; Su B; Gelman IH
J Biol Chem; 2011 Nov; 286(44):38356-38366. PubMed ID: 21903576
[TBL] [Abstract][Full Text] [Related]
14. Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlate with FAK upregulation.
Akakura S; Bouchard R; Bshara W; Morrison C; Gelman IH
Int J Cancer; 2011 Oct; 129(8):2025-31. PubMed ID: 21128249
[TBL] [Abstract][Full Text] [Related]
15. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts.
Cohen SB; Waha A; Gelman IH; Vogt PK
Oncogene; 2001 Jan; 20(2):141-6. PubMed ID: 11313943
[TBL] [Abstract][Full Text] [Related]
16. v-Src suppresses SHPS-1 expression via the Ras-MAP kinase pathway to promote the oncogenic growth of cells.
Machida K; Matsuda S; Yamaki K; Senga T; Thant AA; Kurata H; Miyazaki K; Hayashi K; Okuda T; Kitamura T; Hayakawa T; Hamaguchi M
Oncogene; 2000 Mar; 19(13):1710-8. PubMed ID: 10763828
[TBL] [Abstract][Full Text] [Related]
17. Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS.
Gelman IH; Lee K; Tombler E; Gordon R; Lin X
Cell Motil Cytoskeleton; 1998; 41(1):1-17. PubMed ID: 9744295
[TBL] [Abstract][Full Text] [Related]
18. Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.
Gelman IH
Cancer Metastasis Rev; 2012 Dec; 31(3-4):493-500. PubMed ID: 22684366
[TBL] [Abstract][Full Text] [Related]
19. Ligand-specific control of src-suppressed C kinase substrate gene expression.
Coats SR; Pabón-Peña LM; Covington JW; Vaughan DE
Biochem Biophys Res Commun; 2002 Oct; 297(5):1112-20. PubMed ID: 12372401
[TBL] [Abstract][Full Text] [Related]
20. A novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture.
Lin X; Tombler E; Nelson PJ; Ross M; Gelman IH
J Biol Chem; 1996 Nov; 271(45):28430-8. PubMed ID: 8910468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
